By Christopher Morrison and Nancy Dvorin
Although difficult public financing markets continue to weigh on VC portfolios, particularly in biopharmaceuticals, 2006 demonstrated that the private M&A...
The A-List: 2006's Trend-Shaping Series A Financings
2006's most intriguing Series As reflect VCs' continued emphasis on risk reduction through reprofiling in biotech, and big gains in funding for diagnostics and device start-ups.